Short Name: CANOPTICS
Status: Enrolling

This is an observational study that follows patients at their annual clinic visits. CANOPTICS aims to monitor clinical trends and responses to therapy in people with NMOSD and other atypical demyelinating diseases over time in Canada.

Short Name: SOSTOS
Status: Enrolling

This study investigates if patients who have not had a relapse in the past year would benefit from switching to ofatumumab compared to continuing their current MS treatment. This study also seeks to understand if having an elevated serum neurofilament light (NfL) level can predict a greater benefit from switching to ofatumumab compared to continuing current treatment.

Short Name: PERSEUS
Status: Recruiting soon

To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)

Short Name: MS-DETECT
Status: Recruiting soon

The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS).

The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution. A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients.

Short Name: FREVIVA
Status: Recruiting mid-2024

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.

Short Name: FREXALT
Status: Recruiting mid-2024

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.

Short Name: Fentrepid
Status: Ongoing (closed for enrolment)

Treatment options for Primary Progressive MS (PPMS) are limited, with currently only one disease modifying therapy approved for commercial use by Health Canada.

This study seeks to expand treatment options by evaluating the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS).

Short Name: Consonance
Status: Ongoing (closed for enrolment)

The purpose of this study is to see if ocrelizumab (study drug) will slow the worsening of the signs and symptoms of the progressive form of MS and see how well the study drug is tolerated.

Short Name: GEMINI 1
Status: Ongoing (closed for enrolment)

SAR442168 is a study drug under development for the treatment of MS. SAR442168 is being studied to determine if it will improve physical functioning in subjects with relapsing forms of MS who have disability.

Short Name: OLERO
Status: Enrolling (only participants enrolled in previous trial)

This study aims to continue to collect longer-term information on the safety and effectiveness of treatment with ocrelizumab in subjects with either RMS or PPMS. Participants enrolled in this trial have taken part in previous Parent ocrelizumab studies.

Short Name: CanProCo
Status: Ongoing (closed for enrolment)

This is an observational study designed to better understand the factors that contribute to MS disease progression. It uses tools from different fields such as epidemiology (i.e. number of patients and distribution of diseases), medical imaging (MRI), and immunology (blood). This study will use methods from different scientific areas to evaluate a large group (i.e. cohort) of Canadians living with RRMS, PPMS and RIS over a 5-year period.

Short Name: Sakura Moon
Status: Ongoing (closed for enrolment)

The purpose of this study is to collect more data on the long-term safety and efficacy of satralizumab and to continue providing participants with satralizumab treatment after completion of participation in a previous satralizumab study. Satralizumab has been approved by as a monotherapy or in combination with background immunosuppressive therapy (IST) for the treatment of NMOSD in adult and adolescent patients who are aquaporin-4 (AQP4) antibody seropositive by Health Canada.

Short Name: BTK LTS
Status: Ongoing (closed for enrolment)

The purpose of the study is to determine the long-term safety and tolerability of SAR442168 in participants with relapsing multiple sclerosis (RMS). A secondary purpose is to determine the action of SAR442168 on disease activity by monitoring the lesions in the brain with Magnetic Resonance Imaging (MRI) and evaluating the number of relapses and disability status.

Short Name: Liberto
Status: Ongoing (closed for enrolment)

The purpose of this study is to continue providing treatment with ocrelizumab (a type of drug called a monoclonal antibody) to participants after completion of a previous ocrelizumab clinical trial to see the long-term safety and effectiveness of this drug. Monoclonal antibodies act like your body’s immune system and attach to certain cells to attack germs and other illnesses in your body. Ocrelizumab attaches to certain types of white blood cells (B cells) that are thought to play a role in MS.